Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azenosertib + Encorafenib + Cetuximab in Metastatic Colorectal Cancer
NCT05743036Phase 1Terminated
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Feb 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of azenosertib in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Zentalis Pharmaceuticals. Primary endpoints: Incidence of Dose Limiting Toxicities at 28 days and Objective Response Rate at 12 months. Started Feb 2023; status: terminated.
02
Drugs
azenosertib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05743036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05743036.